# NapaJen Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/napajen-pharma

- Industry: Biotechnology
- Headquarters: Seattle, US
- Website: www.napajen.com
- Total disclosed funding: $27M
- Latest round: Series B (Nov 21, 2016)
- Investors on record: 4

## About

Founded in 2005 and based in California, US, NapaJen Pharma, Inc. is a pharmaceutical company that engages in the research and development of drugs for hematopoietic stem cell transplantation in hematological cancers. The firm was founded as Napa Jenomics Corporation, and initially focused on nucleic acid drug discovery. In March 2024, INCJ, Inc. exited all its stake in NapaJen Pharma, Inc. to KNC Laboratories Co., Ltd.  The firm as of August 2024, has operations internationally, including a subsidiary in Japan, and is led by its CEO, Kenji Arima.

NapaJen Pharma's technology platform addresses the significant challenges of delivering oligonucleotide drugs to target immune cells. By binding directly to the Dectin-1 receptor on antigen-presenting cells, their approach enhances the stability, bioavailability, and cellular uptake of these drugs. This technology accelerates the development process, from target identification to lead optimization. Additionally, the company operates a dual-pronged development strategy, managing both internal drug programs and collaborative projects with biotechnology and pharmaceutical companies. Key offerings include their flagship therapeutic, NJA-730, which is in Phase 1 clinical trials and aims to treat acute graft-versus-host disease (GvHD).

## Funding rounds

- Series B, Nov 21, 2016, $15M — Mitsui Global Investment, INCJ, Mizuho Capital, Nissay Capital
- Series A, Jan 17, 2014, $12M — Mitsui Global Investment, INCJ

## Investors

- Mitsui Global Investment (https://capitalatlas.ai/funds/mitsui-global-investment) — Series A, Series B
- INCJ — Series A, Series B
- Mizuho Capital (https://capitalatlas.ai/funds/mizuho-capital) — Series B
- Nissay Capital (https://capitalatlas.ai/funds/nissay-capital) — Series B